Grace Therapeutics, Inc. Common Stock (GRCE) is a publicly traded Healthcare sector company. As of May 21, 2026, GRCE trades at $2.21 with a market cap of $33.58M and a P/E ratio of -2.75. GRCE moved +1.63% today. Year to date, GRCE is -39.94%; over the trailing twelve months it is -26.54%. Its 52-week range spans $1.75 to $5.18. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces GRCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Issues CRL for Grace Therapeutics’ GTx-104 Citing CMC and Toxicology Gaps: FDA issued a Complete Response Letter for Grace Therapeutics' NDA of GTx-104, citing CMC packaging leachables, nonclinical toxicology assessments, and manufacturing deficiencies. The company plans a Type A meeting with FDA to clarify requirements and resubmit the application addressing these items.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $33.58M |
| P/E Ratio | -2.75 |
| EPS | $-0.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.18 |
| 52-Week Low | $1.75 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-9.57M |
| Gross Margin | 0.00% |
2 analysts cover GRCE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.